Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI113423

Intracoronary infusion of dobutamine to patients with and without severe congestive heart failure. Dose-response relationships, correlation with circulating catecholamines, and effect of phosphodiesterase inhibition.

W S Colucci, A R Denniss, G F Leatherman, R J Quigg, P L Ludmer, J D Marsh, and D F Gauthier

Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts 02115.

Find articles by Colucci, W. in: PubMed | Google Scholar

Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts 02115.

Find articles by Denniss, A. in: PubMed | Google Scholar

Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts 02115.

Find articles by Leatherman, G. in: PubMed | Google Scholar

Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts 02115.

Find articles by Quigg, R. in: PubMed | Google Scholar

Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts 02115.

Find articles by Ludmer, P. in: PubMed | Google Scholar

Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts 02115.

Find articles by Marsh, J. in: PubMed | Google Scholar

Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts 02115.

Find articles by Gauthier, D. in: PubMed | Google Scholar

Published April 1, 1988 - More info

Published in Volume 81, Issue 4 on April 1, 1988
J Clin Invest. 1988;81(4):1103–1110. https://doi.org/10.1172/JCI113423.
© 1988 The American Society for Clinical Investigation
Published April 1, 1988 - Version history
View PDF
Abstract

We infused dobutamine into the left main coronary artery of 24 patients with severe congestive heart failure (CHF) and 8 normal subjects without hemodynamic dysfunction. The maximal +dP/dt response to intracoronary (IC) dobutamine in CHF patients was only 37% of that in normals. This decrease in maximal response was not associated with a rightshift in the EC50 for dobutamine's effect on +dP/dt, or a decrease in the affinity of myocardial beta adrenergic receptors for dobutamine determined in vitro. In nine of the CHF patients, IC dobutamine infusion was followed by IC infusion of the phosphodiesterase inhibitor milrinone, and subsequently, by a second IC infusion of dobutamine. After IC milrinone, the increase in +dP/dt caused by IC dobutamine (74 +/- 10%) was significantly greater than that caused by the first infusion of dobutamine (52 +/- 11%; P less than 0.003) or milrinone (42 +/- 6%; P less than 0.001). Resting plasma norepinephrine was markedly elevated in CHF patients (837 +/- 208 ng/liter), but not in normal subjects (142 +/- 32 ng/liter); and the increase in +dP/dt caused by IC dobutamine was inversely related to resting plasma norepinephrine levels (r = -0.653; P less than 0.001). IC dobutamine caused a dose-related decrease in plasma norepinephrine (maximal effect, -160 +/- 31 ng/liter; P less than 0.001). Thus, (a) the maximal inotropic response to dobutamine is markedly depressed in patients with severe CHF, and is significantly greater after pretreatment with the phosphodiesterase inhibitor milrinone; (b) the impairment in inotropic response to dobutamine is inversely related to circulating norepinephrine levels; and (c) myocardial stimulation by dobutamine results in withdrawal of sympathetic tone.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 1103
page 1103
icon of scanned page 1104
page 1104
icon of scanned page 1105
page 1105
icon of scanned page 1106
page 1106
icon of scanned page 1107
page 1107
icon of scanned page 1108
page 1108
icon of scanned page 1109
page 1109
icon of scanned page 1110
page 1110
Version history
  • Version 1 (April 1, 1988): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts